To the Editor: A 38-year-old, HIV-seropositive Nigerian man sought treatment with an 8-month history of severe parietal headache, impaired memory, fatigue, paresthesia of the left arm, and left-sided focal seizures. He had no history of neurologic disorders, including epilepsy. On physical examination, the patient appeared well, alert, and oriented, with slurred speech. Evaluation of the visual fields showed left homonymous hemianopsia. All other neurologic assessments were unremarkable. The patient had a blood pressure of 120/80, a pulse of 88 beats per minute, and a body temperature of 37.3°C. Leukocyte count was 10,921/L, total lymphocyte count was 4,591/L, CD4+ cell count was 13 µL, HIV-load was <50 copies/mL, and a MRI scan of the brain showed partial regression of the 2 brain lesions (Figure D).

Chrysosporium spp. are common soil saprobes, occasionally isolated from human skin. Invasive infection is very rare in humans, and most were observed in immunocompromised patients, manifesting as osteomyelitis (3,4) or diffuse vascular brain invasion (5). Here, we report the first case of brain abscesses by the Chrysosporium anamorph of Nannizziosis vriesii. This fungus has been associated with fatal mycosis in reptiles (6,7) and cutaneous mycosis in chameleons (8–10) and cutaneous mycosis in chameleons (8). This fungus has been associated with fatal mycosis in reptiles (6,7) and cutaneous mycosis in chameleons (8). This fungus has been associated with fatal mycosis in reptiles (6,7) and cutaneous mycosis in chameleons (8–10) and cutaneous mycosis in chameleons (8).
LETTERS

skin lesions were present at the time of admission. However, the multifocal nature, lung infiltration, and involvement of the middle cerebral artery distribution suggest hematogenous dissemination after replication of airborne conidia within the respiratory tract.

Fungi cause >90% of brain abscesses in immunocompromised transplant patients with an associated mortality rate of 97% (9), despite aggressive surgery and antifungal therapy (9). Our patient was treated successfully with abscess drainage, antiretroviral therapy, and oral voriconazole, a novel antifungal triazole drug. Despite limited data available on voriconazole penetration into brain abscess cavities (9), this drug was clinically and radiologically effective in our patient.

Acknowledgments

We thank the patient for cooperating with our investigation, Pfizer Germany for providing voriconazole, and Heidemarie Losert and Elisabeth Antweiler for their excellent technical assistance.

Christoph Steininger,*
Jan van Lunzen,*
Kathrin Tintelnot,†
Ingo Sobottka,* Holger Rohde,*
Matthias Anser Horstkotte,*
and Hans-Jürgen Stellbrink*

*University Clinic Eppendorf, Hamburg, Germany; and †Robert Koch-Institut, Mykologie, Berlin, Germany

References


Address for correspondence: Christoph Steininger, University Clinic Eppendorf, Department of Medicine I, Infectious Diseases Unit, Martinistrasse 52, 20246 Hamburg, Germany; fax: 49-40-42803-6832; email: c.steininger@uke.uni-hamburg.de

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

Figure. Chrysosporium sp. brain abscess in an HIV-seropositive patient. A) T2-weighted magnetic resonance imaging (MRI) scan of the brain showing 2 large masses (triangles) surrounded by a ring of signal intensity and extensive perifocal edema (open arrows), global swelling of the right hemisphere, and a midline shift of 1.2 cm. B) Computed tomographic scan of the chest showing infiltration of the left and right lower segment. C) Mold mycelium in aspirate of brain abscess with calcoflour white stain. D) T2-weighted MRI scan of the brain performed 4 months after beginning of therapy.